SARATOGA SPRINGS — As part of Fingerpaint’s continued commitment to bring forward the best opportunities to their clients, the full-service health and wellness marketing agency has acquired 1798, a market access and commercialization firm located in La Jolla, CA.
Biopharmaceutical manufacturers have entered a new era wherein a primary consideration is now how their products will allow healthcare professionals to provide cost-efficient, value-driven, quality care to patients. Today, the expectation is that these life sciences companies expertly communicate well-thought-out, market-responsive data demonstrating not only the clinical benefit of a product, but also its impact on cost of care. The 60-person team at 1798 specializes in developing tailored market access and commercialization support programs for drugs at any stage in the product life cycle (from early to late product stages). The acquisition of this well-respected, experienced managed markets firm will allow Fingerpaint to offer their life sciences clients a wealth of new healthcare consulting services, including patient and provider access services, financial impact analysis and analytics, competitive intelligence, pull-through solutions, account leader support materials, and training materials.
“With the acquisition of 1798, Fingerpaint will be able to assure our life sciences clients that we can provide the full continuum of market access planning and commercialization support services to successfully assist them in building their brands and launching new products,” said Ed Mitzen, founder of Fingerpaint. “We are honored and excited that 1798 is joining the
Fingerpaint family.”
Roshawn Blunt, a former biopharmaceutical company senior executive with experience in hospital administration and the founder of 1798, stated, “It was a welcome opportunity to join a great creative powerhouse within the health and wellness industry, and we look forward to a synergistic relationship that will provide elegant solutions and superior outcomes for our clients.”
Mitzen and Blunt, along with the rest of the leadership team, will work hand-in-hand to continue delivering a competitive advantage and customized approaches to their clients, from early-stage commercialization to overcoming challenges that occur post-launch in the commercialization process.Terms of the deal were not disclosed.
